Metipranolol
| Evidence Level: L4 | Predicted Indications: 3 |
Table of Contents
Metipranolol: From Open-Angle Glaucoma to Primary Hereditary Glaucoma
One-Sentence Summary
Metipranolol is a topical non-selective beta-blocker traditionally used to lower intraocular pressure (IOP) in chronic open-angle glaucoma and ocular hypertension. The TxGNN model predicts a very high likelihood of relevance to Primary Hereditary Glaucoma, but this specific link currently has no clinical trials and no dedicated literature — the prediction rests on mechanistic extrapolation from the drug’s established beta-blocker pharmacology.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Chronic open-angle glaucoma / ocular hypertension (established topical IOP-lowering therapy; no UK marketing authorisation currently on record in this evidence pack) |
| Predicted New Indication | Primary Hereditary Glaucoma |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L4 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
DrugBank does not currently hold a formal mechanism-of-action record for metipranolol (data gap). Based on the pharmacological information available in this evidence pack, metipranolol is a non-selective beta-adrenergic receptor antagonist applied topically to the eye. It blocks beta-2 receptors on the ciliary body epithelium, reducing aqueous humour production and thereby lowering intraocular pressure — the central pathophysiological target in glaucoma.
Primary hereditary glaucoma (encompassing genotype-defined subgroups such as primary congenital glaucoma and juvenile open-angle glaucoma) shares the same core pathology of elevated IOP as classic open-angle glaucoma, so the beta-blocker mechanism is theoretically applicable. However, these hereditary forms — particularly congenital-onset disease — are typically managed with surgery as first-line treatment, and no genotype-specific clinical trials or publications currently exist for metipranolol in this population.
Notably, a related and much better-supported prediction in this evidence pack (open-angle glaucoma, TxGNN score 99.35%) is backed by 20 publications including multiple RCTs (evidence level L1), confirming metipranolol’s established efficacy in lowering IOP in the classic disease phenotype. This lends indirect mechanistic credibility to the hereditary-glaucoma hypothesis, even though it does not substitute for direct evidence in that specific population.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
UK Market Information
No UK marketing authorisations are currently on record for metipranolol in this evidence pack (market status: Not marketed; total licences: 0). Marketing authorisation status should be verified directly with the MHRA product register before any regulatory or clinical planning proceeds.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Note: TFDA-equivalent warning/contraindication data and formal MOA documentation are flagged as outstanding data gaps (one of which is blocking for safety pre-assessment) and should be resolved before clinical evaluation advances — see Next Steps below.
Conclusion and Next Steps
Decision: Hold
Rationale: The predicted indication (primary hereditary glaucoma) currently has zero supporting clinical trials or publications, and evidence level L4 reflects a mechanism-only rationale rather than direct clinical data. Hereditary/congenital glaucoma subtypes are also typically treated surgically as first-line, which limits the practical applicability of a topical beta-blocker without further evidence.
To proceed, the following is needed:
- UK/EU SmPC-level safety data (key warnings, contraindications) — currently a blocking data gap
- Formal MOA documentation from DrugBank to support mechanistic-relevance analysis
- Genotype-stratified clinical evidence for specific hereditary glaucoma subpopulations (e.g., primary congenital glaucoma, juvenile open-angle glaucoma)
- Confirmation of UK marketing authorisation status/pathway, given metipranolol is not currently marketed in the UK
- Consideration of the stronger, already-established open-angle glaucoma evidence base (L1, 20 publications) as supportive — but not substitutive — context when designing any hereditary-glaucoma study
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.